Furthermore, our findings suggest a possible predictive role of p53 status in iCCA patients treated with gemcitabine; however, due to the small patients’ population included in the present study, the results should be considered as preliminary, and need to be confirmed in further investigations on a larger patients’ population. This evidence concerns the gene TP53 and infantile convulsions and choreoathetosis.